Johnson & Johnson Launches Dual-Energy Cardiac Ablation Catheter in Europe

Johnson & Johnson (NYSE:JNJ) announced on June 25 the commercial launch of the Dual Energy THERMOCOOL SMARTTOUCH SF (DE STSF) platform in Europe. The platform is now commercially available to electrophysiologists across the EMEA region for the treatment of atrial fibrillation.

The Product

The platform features the ability to use both radiofrequency and microwave energy in a single catheter, allowing physicians to tailor treatment to patient needs. The technology aims to improve ablation precision and reduce procedure time.

Pricing and Availability

The company has not disclosed pricing details. The platform is currently available in select European markets within the EMEA region.

Competition

Johnson & Johnson faces competition from Medtronic and Boston Scientific, which offer advanced cardiac ablation technologies. However, the DE STSF platform differentiates itself with dual-energy capability.

Potential Impact on the Company

The new launch is expected to strengthen Johnson & Johnson's position in the growing electrophysiology device market, potentially supporting medical device segment revenue. The stock (JNJ) has not shown significant movement following the announcement.